The study, "A Breath of Life Beyond Bronchodilation: Early Data on Hemodynamic and Functional Outcomes With Ensifentrine Nebulization in Severe COPD-associated Pulmonary Hypertension," was carried out by Ramakanth Pata, Joanna Kristeva, Mallory Illies, and Justin Stocks.
A small but carefully documented retrospective case series from a US pulmonary hypertension clinic reports that nebulized ensifentrine an inhaled dual phosphodiesterase 3/4 inhibitor approved in 2024 for moderate-to-severe COPD, was associated with modest but consistent improvements in pulmonary hemodynamics, exercise capacity, and patient-reported breathlessness over six months in patients with severe COPD-associated pulmonary hypertension, without provoking exacerbations, worsening oxygenation, or significant adverse events. To the authors' knowledge, this is the first published report evaluating ensifentrine specifically in patients with COPD-associated pulmonary hypertension confirmed by right heart catheterization.
Clinical Context and Rationale
Pulmonary hypertension (PH) complicates advanced COPD in an estimated 13% to 64% of patients, with a pooled prevalence of approximately 39% reported in recent meta-analyses. It arises from chronic hypoxic vasoconstriction and progressive remodelling of the pulmonary vasculature, resulting in increased right ventricular afterload, reduced exercise tolerance, and substantially worsened survival. Despite its clinical importance, no pharmacological therapy is currently approved specifically for COPD-associated PH. Current guidelines recommend optimisation of underlying COPD management and long-term oxygen therapy as the primary interventions, while conventional pulmonary vasodilators including phosphodiesterase-5 inhibitors and endothelin receptor antagonists carry a risk of worsening ventilation-perfusion mismatch through non-selective vasodilation of poorly ventilated lung regions and are generally reserved for expert centres or clinical trials. Ensifentrine's inhaled delivery offers a theoretically more favourable profile in this context: by acting directly and preferentially within better-ventilated lung regions, it may produce pulmonary vasodilation and anti-inflammatory effects with reduced risk of systemic hypotension or oxygen desaturation. Its dual mechanism PDE3 inhibition promotes smooth muscle relaxation in airways and pulmonary vessels, while PDE4 inhibition attenuates cytokine-mediated vascular inflammation provides a mechanistically plausible rationale for evaluating it in this under-served patient population.
Study Design and Findings
The research team at the CentraCare Health System in Minnesota conducted a single-centre retrospective chart review of patients with confirmed pre-capillary pulmonary hypertension (mean pulmonary artery pressure ≥20 mmHg, pulmonary vascular resistance >2 Wood units, pulmonary capillary wedge pressure ≤15 mmHg on right heart catheterisation) and GOLD Stage III–IV COPD who received nebulised ensifentrine at 3 mg twice daily between September 2024 and May 2025. Of 14 patients initially screened, five met the full inclusion criteria and completed repeat right heart catheterisation and six-minute walk testing at six months. The cohort had a mean age of 76 years, mean FEV1 of 33.4% predicted, mean baseline mean pulmonary artery pressure of 53.2 mmHg, and mean pulmonary vascular resistance of 9.5 Wood units reflecting both severe obstructive lung disease and haemodynamically significant pulmonary hypertension. All five patients were on maximal guideline-directed COPD therapy, including inhaled triple therapy, long-term oxygen, and in most cases non-invasive ventilation, roflumilast, chronic azithromycin, and pulmonary rehabilitation. After six months, mean pulmonary artery pressure fell modestly from 53.2 to 51.6 mmHg, pulmonary vascular resistance decreased from 9.5 to 8.5 Wood units, and cardiac index rose marginally from 2.5 to 2.6 L/min/m². Six-minute walk distance improved by a mean of 31 metres (from 224 m to 255 m), and patient-reported dyspnea improved on both the modified Medical Research Council scale (3.6 to 3.2) and the COPD Assessment Test (23 to 21.6). Diffusing capacity for carbon monoxide showed a small increase (29% to 31.2% predicted), while FEV1 remained essentially unchanged, consistent with the advanced emphysematous phenotype of this cohort and the absence of significant residual reversible airflow limitation. No exacerbations, hospitalisations, weight loss, liver dysfunction, depression, or worsening oxygenation were observed. The combination of ensifentrine and roflumilast, which four of five patients received concurrently, was well tolerated in all cases.
Interpretation, Limitations, and Future Directions
The authors present these findings explicitly as hypothesis-generating and are careful to circumscribe their conclusions accordingly. With only five patients, no control group, and an inherently retrospective design subject to selection bias, nine of the original fourteen patients were excluded, predominantly for clinical instability or logistical barriers to repeat catheterisation no statistical inference is possible, and the observed improvements cannot be attributed to ensifentrine with confidence. It remains unclear whether the changes in haemodynamics and functional capacity reflect a direct pharmacological effect, measurement variability, the influence of optimised concurrent therapy, or natural fluctuation in disease state. The authors also note that inflammatory biomarkers were not collected, limiting evaluation of the drug's putative anti-inflammatory contribution. Nonetheless, the consistency of directional improvement across haemodynamic, functional, and symptom-based measures in a cohort with very limited therapeutic options, and the absence of the ventilation-perfusion mismatch and oxygenation concerns that have historically constrained use of systemic vasodilators in this setting, provides sufficient signal to justify formal prospective investigation. The authors call for multicentre randomised controlled trials with pre-specified haemodynamic and functional co-primary endpoints, as well as mechanistic substudies using cardiac magnetic resonance imaging and gas exchange assessment to clarify whether the observed effects are driven by direct vascular action, improved airflow, or both. The research was led by corresponding author Dr. Ramakanth Pata of the Division of Pulmonary and Critical Care Medicine, CentraCare Health System, Minnesota, USA, alongside co-authors Dr. Joanna Kristeva, Dr. Mallory Illies, and Dr. Justin Stocks, all of the same institution.
Read the published article here: https://bit.ly/4rIm43S
Article title: A Breath of Life Beyond Bronchodilation: Early Data on Hemodynamic and Functional Outcomes With Ensifentrine Nebulization in Severe COPD-associated Pulmonary Hypertension
Journal : The Open Respiratory Medicine Journal
DOI: 10.2174/0118743064456019260621185404
The Open Respiratory Medicine Journal
10.2174/0118743064456019260621185404
A Breath of Life Beyond Bronchodilation: Early Data on Hemodynamic and Functional Outcomes With Ensifentrine Nebulization in Severe COPD-associated Pulmonary Hypertension